Shakil, Saate S
Temu, Tecla M
Kityo, Cissy
MMed, Geoffrey Erem MBChB
Bittencourt, Marcio S
Longenecker, Chris T
Funding for this research was provided by:
National Institutes of Health (T32 HL007828, 1K01 HL147723, K23 HL123341)
Article History
Received: 3 October 2022
Accepted: 9 June 2023
First Online: 19 June 2023
Declarations
:
: CTL has received research grants from Gilead Sciences and Medtronic Foundation and has served on the board of Esperion Therapeutics. The other authors have no disclosures.
: The study was reviewed and approved by the Institutional Review Boards of University Hospitals Cleveland Medical Center, the Joint Clinical Research Centre (Kampala), and by the Uganda National Council for Science and Technology. All participants provided written informed consent. All study procedures were carried out in accordance with the relevant guidelines and regulations, including the Declaration of Helsinki.
: Not applicable.